SEC Form 4 · accession 0001140361-18-001507
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 8:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 5, 2018 | M | 10,000 | $38.59 | A | 235,894 | D | |
| Common StockF1,F2 | Jan 5, 2018 | S | 10,000 | $90.3203 | D | 225,894 | D | |
| Common Stock | holding | — | — | — | 182,801 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $38.59 | Jan 5, 2018 | M | 10,000 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 10,000 | 182,500 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $89.81 to $90.82. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.